- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- What’s driving physicians to early retirement
- Why Tenet’s CEO says ASCs keep choosing USPI
- 12 recent hospital, health system president exits
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- 32 health systems spending $5B on cancer care
- Sanford, North Memorial planned combination adds to Minnesota healthcare deal wave
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- UT Austin launches Epic ahead of new academic medical center
- Ohio system names COO
- Buy, sell or fight: The new calculus of health system growth
- OpenAI’s growing healthcare footprint
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Why Cook County Health’s Medicaid coverage loss strategy is drawing attention
- Akron Children’s chosen for former Ohio college campus site
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- The growing war over Anthem’s out-of-network penalty policy
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Could ASCs help cardiology move past its ‘breaking point’?
- 3 programs expanding the anesthesia workforce in 2026
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- UVM Health targets $300M in cuts, outpatient overhaul amid $280M deficit
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- 5 data breaches, settlements impacting cardiology
- Maine hospital adds stroke prevention, cardiac imaging services
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- Trump plans to fire FDA chief Marty Makary: report
- Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Pennsylvania enacts dental faculty bill
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- New York expands behavioral health data access in EHRs
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- New Hampshire to receive $29.5M in Purdue opioid settlement
- Behavioral health leaders counter HHS ‘overprescribing’ narrative
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Alnylam rebuked by FDA over efficacy claims on Amvuttra website
- Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Sanofi asks to pull Tzield bid from FDA's controversial CNPV program: report
- FDA rolls out 1-day assessment pilot in bid to refocus inspection resources
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Novo CEO cites pricing 'sweet spot' as Wegovy pill debuts with $355M quarter
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- FDA blocks publication of COVID, shingles vaccine safety studies: NYT
- Bayer diagnoses how to build trust in cell and gene therapies
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Hinge Health lifts 2026 outlook after strong Q1 as it expands to new conditions
- For nonprofit hospitals, pricey management consultants haven't yielded better performances: study
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Wellstar partners with BD to implement AI-driven medication management system
- Listen to the Latest ‘KFF Health News Minute’
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
- Surgeon Multitasking Increases Death Risk Of Organ Transplantees
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
Obviously, these "behavioral science" results aren't to be trusted. The really tricky policy question is identifying the special interest behind it. Who benefits from skewing this data?
And the real-world conundrum: how much "behavioral health science" is also on shaky ground?
Francesca Gino, a prominent Harvard Business School professor, alleged to have falsified results in behavioral science studiesOver the last few weeks, allegations have surfaced against Francesca Gino, a prominent Harvard Business School (HBS) professor who has been accused of falsifying results in several behavioral science studies.
On 16 June, the Chronicle of Higher Education reported that Max Bazerman, a HBS professor and co-author who published a paper in 2012 alongside Gino, said that Harvard informed him that it believed one of the studies overseen by Gino had falsified results.
The paper in question is on findings published in – and later retracted by – the Proceedings of the National Academy of Sciences and surrounds an experiment that asked participants to fill out tax and insurance paperwork.
“Many written forms required by businesses and governments rely on honest reporting. Proof of honest intent is typically provided through signature at the end of, eg, tax returns or insurance policy forms. Still, people sometimes cheat to advance their financial self-interests at great costs to society. We test an easy-to-implement method to discourage dishonesty: signing at the beginning rather than at the end of a self-report, thereby reversing the order of the current practice,” the paper’s abstract read.
The study claimed to have discovered that participants who were asked to sign truthfulness declarations at the top of the page were more honest than those who were asked to sign the declarations at the bottom of the page.
According to the Chronicle of Higher Education, Bazerman said that the university provided a 14-page document that included “compelling evidence” of data falsification, including the discovery that someone accessed a database and added and altered data in the file. He went on to deny any involvement in the alleged data tampering, telling the Chronicle: “I did not have anything to do with the fabrication.”
A day later, a blog called DataColada and run by three behavioral science academics published a four-part series of posts that detailed extensive evidence of the alleged fraud in four academic papers co-authored by Gino.
“We discovered evidence of fraud in papers spanning over a decade, including papers published quite recently (in 2020),” the blog authors, ESADE Business School’s Uri Simonsohn, University of California, Berkeley’s Leif Nelson, and University of Pennsylvania’s Joseph Simmons, wrote.
“In the fall of 2021, we shared our concerns with Harvard Business School. Specifically, we wrote a report about four studies for which we had accumulated the strongest evidence of fraud. We believe that many more Gino-authored papers contain fake data. Perhaps dozens,” the scholars said.
“We understand that Harvard had access to much more information than we did, including, where applicable, the original data collected using Qualtrics survey software. If the fraud was carried out by collecting real data on Qualtrics and then altering the downloaded data files, as is likely to be the case for three of these papers, then the original Qualtrics files would provide airtight evidence of fraud. (Conversely, if our concerns were misguided, then those files would provide airtight evidence that they were misguided),” they added.
To the best of their knowledge, none of Gino’s co-authors carried out or assisted with the data collection for the studies in question, the scholars said.
According to Gino’s HBS profile, she is currently on administrative leave.
Speaking to the New York Times, a man who identified himself as Gino’s husband said: “It’s obviously something that is very sensitive that we can’t speak to now.”
Faulty tools, faulty results.
Today Morning Brew delivers a concise description of the Excel flaw that skewed gene studies.
Microsoft updates Excel feature that caused problems for scientists
The feature, known as Automatic Data Conversion, converted certain human gene names into dates and created massive errors in scientific research.
Microsoft is finally tweaking an Excel feature that has caused nearly two decades of grief for scientists. The feature, known as Automatic Data Conversion, which in the past constantly converted certain human gene names into dates and created massive errors in scientific research, can now be disabled.
If your science background is more Intro to Geology…every one of the nearly 44,000 human genes has a shortened version of its name and a symbol. So when a scientist typed SEPT1 to represent the Septin-1 gene in an Excel sheet, the program would assume they meant September 1 and change it. And if you’ve ever been the dogsbody who has to comb through an Excel file, you know it’s easy to miss a tiny error like this.
But those tiny errors amounted to big problems: A study of 10,000 scientific papers on genes published from 2014–2020 found that more than 30% contained a gene name error that was Excel's fault. It got so bad that by 2020 the governing body behind gene naming had updated 27 gene names so they couldn’t be mistaken in the Microsoft program (i.e. SEPT1 became SEPTIN1).
How to turn it off: You can now personalize Excel’s auto correcting functions under File>Options>Data.
https://www.morningbrew.com/daily/stories/updates-excel-caused-problems-scientists30% in 17 years.
3,000 papers in genes. That's a lot of research, and it touches a lot of lives.
Wonder how many drugs were impacted?
Is this part of the reason for the pre/post-release discrepancies in so many drugs?
Is the current rush to capture all Sickle Cell carriers founded on any of these errors?
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.













